At the current price, the estimated financial resources required to progressively expand access to PD1/PD-L1 inhibitors as monotherapies for advanced NSCLC in all countries over 10 years are significant compared to the current and projected pharmaceutical expenditure, casting doubt on the feasibility of achieving equitable access in lower-income countries. The gene discussed is CD274; the disease is non-small cell lung carcinoma.